Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study

Journal of Clinical Lipidology

Volumn 5, Issue 4, 2011, Pages 316-323

  Idris, Iskandar ^a,b   Tate, Helen ^c   Ahmad, Azhar ^c   McCormack, Terry ^d  

^a SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c Merck Sharp & Dohme Limited   (United Kingdom)

^d Whitby Group Practice   (United Kingdom)

Author keywords

ApoB; Concordance; LDL cholesterol; nonHDL cholesterol; On treatment

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; KAPPA STATISTICS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

AGED; APOLIPOPROTEINS B; AZETIDINES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES;

EID: 79960824737     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.06.001     Document Type: Article

References (25)

1. P.M. Kearney, L. Blackwell, R. Collins Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125l
2. M.H. Davidson Reducing residual risk for patients on statin therapy: the potential role of combination therapy Am J Cardiol 7 96 2005 3K 13K (Pubitemid 41598106)
3. J.C. Fruchart, F.M. Sacks, and M.P. Hermans Residual Risk Reduction Initiative (R3I). Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient Diab Vasc Dis Res 5 2008 319 335
4. W.C. Cromwell, and J.D. Otvos Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl Am J Cardiol 98 2006 1599 1602 (Pubitemid 44827965)
5. A.D. Sniderman, A.C. St-Pierre, B. Cantin, G.R. Dagenais, J.-P. Despres, and B. Lamarche Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk Am J Cardiol 91 2003 1173 1177 (Pubitemid 36561379)
6. C.M. Ballantyne, T.C. Andrews, J.A. Hsia, J.H. Kramer, C. Shear ACCESS Study Group Atorvastatin Comparative Cholesterol Efficacy and Safety Study Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels Am J Cardiol 88 2001 265 269 (Pubitemid 32721953)
7. J.J. Kastelein, W.A. van der Steeg, I. Holme SM; TNT Study Group; IDEAL Study Group Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
8. De Graaf, P. Couture, and A. Sniderman A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinaemias Nat Clin Pract Endocrinol Metab 4 2008 608 618
9. J.D. Otvos, E.J. Jeyarajah, and W.C. Cromwell Measurement issues related to lipoprotein heterogeneity Am J Cardiol 17 90 2002 22i 29i (Pubitemid 35284908)
10. A.M. Gotto Jr., E. Whitney, and E.A. Stein Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Circulation 101 2000 477 484 (Pubitemid 30080860)
11. T.R. Pedersen, A.G. Olsson, and O. Faergeman Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation 97 1998 1453 1460 (Pubitemid 28191300)
12. R.J. Simes, I.C. Marschner, D. Hunt LIPID Study Investigators Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105 2002 1162 1169 (Pubitemid 34225815)
13. J.E. van Lennep, H.T. Westerveld, H.W. van Lennep, A.H. Zwinderman, D.W. Erkelens, and E.E. van der Wall Apolipoprotein concentrations during treatment and recurrent coronary artery disease events Arterioscler Thromb Vasc Biol 20 2000 2408 2413
14. J.D. Brunzell, M. Dabidson, C.D. Furberg American Diabetes Association; American College of Cardiology Foundation Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 31 2008 811 822
15. T. McCormack, P. Harvey, R. Gaunt, V. Allgar, R. Chipperfield, and P. Robinson Incremental cholesterol reduction with ezetemibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets Int J Clin Pract 64 2010 1052 1061
16. W. Lu, H.E. Resnick, and K.A. Jablonski Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study Diabetes Care 26 2003 16 23 (Pubitemid 36928989)
17. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
18. M.J. McQueen, S. Hawken, X. Wang INTERHEART study investigators 8 Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study Lancet 372 2008 224 233 (Pubitemid 351978112)
19. A. Sniderman, M. McQueen, J. Contois, K. Williams, and C.D. Furberg Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol J Clin Lipidol 4 2010 152 155
20. S.J. Robins, D. Collins, J.T. Wittes VA-HIT Study Group Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591 (Pubitemid 32240250)
21. J.H. O'Keefe Jr., L. Cordain, W.H. Harris, R.M. Moe, and R. Vogel Optimal low-density lipoprotein is 50-70 mg/dl: lower is better and physiologically normal J Am Coll Cardiol 43 2004 2142 2146 (Pubitemid 38686815)
22. R. Rosense, and D. Lloyd-Jones Critical appraisal of revised cholesterol guidelines for the very high-risk patient Expert Rev Cardiovasc Ther 3 2005 1 7
23. I. Idris, and F. Al-Ubaidi Discordance between non-HDL cholesterol and LDL cholesterol levels in patients with diabetes without previous cardiovascular events Diabetes Metab 36 2010 299 304
24. S. Kathiresan, J.D. Otvos, and L.M. Sullivan Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study Circulation 113 2006 20 29 (Pubitemid 43958484)
25. W.T. Garvey, S. Kwon, and D. Zheng Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance Diabetes 52 2003 453 462 (Pubitemid 36173203)